Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myelomaTorben Plesner, Paul G. Richardson, Charlotte Lemech et al.|Blood|2016Cited by 110
Daratumumab in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Updated Results of a Phase 1/2 Study (GEN503)Torben Plesner, Paul G. Richardson, Hendrik‐Tobias Arkenau et al.|Blood|2015Cited by 40